Related references
Note: Only part of the references are listed.Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Rui Guo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Takashi K. Kishimoto et al.
NATURE NANOTECHNOLOGY (2016)
K Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
Gilad Kaplan et al.
TOXINS (2016)
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
William R. Strohl
BIODRUGS (2015)
Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo
Sung In Lim et al.
JOURNAL OF CONTROLLED RELEASE (2015)
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans-PK/PD and Safety
R. L. O'Connor-Semmes et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
John E. Weldon et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
John E. Weldon et al.
FEBS JOURNAL (2011)
Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
PEGylation of therapeutic proteins
Simona Jevsevar et al.
BIOTECHNOLOGY JOURNAL (2010)
Alternative binding proteins:: Affibody binding proteins developed from a small three-helix bundle scaffold
Per-Ake Nygren
FEBS JOURNAL (2008)
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients
M Ho et al.
CLINICAL CANCER RESEARCH (2005)
Mesothelin: A new target for immunotherapy
R Hassan et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
